What are the claims
Kevin Sheng-Kai Ma, DDS, FRSPH, FRSM, international scholar at the Center for Global Health at the Perelman School of Medicine at the University of Pennsylvania and lead author of this study, told Medical News Today that he and his colleagues were not surprised by these findings, as these [obesity and obesity-related issues] are indications for GLP-1RA that have been approved in recent years. That said, clinicians are encouraged to monitor and continue assessing patients receiving GLP-1RA [drugs], he advised
Regulatory Status as of Mid-2026 The July 2026 advisory committee vote FDAs Pharmacy Compounding Advisory Committee met on 2324 July 2026 to consider seven peptides for the Section 503A Bulk Drug Substances List
Hypoglycaemia risk increases when GLP-1 agonists are combined with insulin or sulphonylureas, requiring careful medication review and dose adjustment
Risks associated with mass-produced compounded GLP-1s Although the FDA has declared that the supply shortage is resolved, some companies continue to mass produce compounded versions of GLP-1s, claiming that the drugs are personalized for patient needs by altering the method of delivery (e.g., gummy, injection, spray) or adding unnecessary and unproven ingredients like B12 and glycine
If they dont I see it as a red flag